ANI Pharmaceuticals (ANIP) vs Generate Biomedicines (GENB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Generate Biomedicines is the larger company by market cap ($1.69 billion vs $1.66 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | GENB |
|---|---|---|
| Share price | $72.19 | $13.21 |
| Market cap | $1.66B | $1.69B |
| 1-day change | +0.36% | -2.69% |
| YTD return | -8.88% | — |
| 1-year return | -21.54% | — |
| 5-year return | +86.64% | — |
| P/E ratio (TTM) | 15.63 | — |
| Forward P/E | 7.10 | — |
| EPS (TTM) | $4.62 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.00 | $22.67 |
| 52-week low | $69.58 | $11.00 |
| Distance from 52-week high | -25.58% | -41.75% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +46.53% | +104.47% |
| Average volume | 372.56K | 1.04M |
| Shares outstanding | 22.96M | 128.35M |
| Employees | 970 | 312 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
ANIP vs GENB FAQ
Which is bigger, ANI Pharmaceuticals or Generate Biomedicines?
Generate Biomedicines (GENB) is larger, with a market capitalization of $1.69B compared with $1.66B for ANI Pharmaceuticals (ANIP).
Are ANI Pharmaceuticals and Generate Biomedicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.